NCT07626515
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Primary and study completion moved earlier from May 14, 2027 to Apr 8, 2027
- Site details revised
- Notable Eligibility criteria expanded, about 9 words
- Minor Primary completion date: Apr 30, 2027 to May 14, 2027
- Study completion date: May 30, 2027 to May 14, 2027
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Jun 26, 2026 to Jul 2, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence and Severity of Adverse Events
Timeframe: Baseline to Safety Follow-Up (27 weeks)
Number of Participants with Abnormal Clinical Laboratory Parameters as a Shift from Baseline to Maximum Postbaseline Severity Grade
Timeframe: Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Pulse Rate
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Respiratory Rate
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Systolic Blood Pressure
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Diastolic Blood Pressure
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Body Temperature
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Secondary (7)
Plasma Concentration of Enicepatide
Maximum Plasma Concentration Observed (Cmax) of Enicepatide
Time to Cmax (Tmax) of Enicepatide
Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUClast) of Enicepatide
Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Enicepatide
Show 2 moreShow less
Absolute Change From Baseline in Body Weight
Percent Change From Baseline in Body Weight
Arms and interventions
Enicepatide Dose 1Experimental
Enicepatide Dose 2Experimental
PlaceboPlacebo comparator
Combination products: Enicepatide, Placebo
Sites
1 site in 1 country
- Peking University First HospitalBeijing, China